Total amount: € 0,00
Online ISSN 1827-1596
Dimopoulos G. 1, Armaganidis A. 1, Poulakou G. 2, Matthaiou D. K. 2
1 Department of Critical Care, Medical School, University of Athens, “Attikon” University Hospital, Athens, Greece;
2 .4th Department of Internal Medicine, Medical School, University of Athens, “Attikon” University Hospital, Athens, Greece
Rituximab is a monoclonal chimeric antibody used in the treatment of CD20-positive B-cell malignancies and rheumatoid arthritis. However, it is used in several other off-label indications including acute graft-versus-host disease. We sought to critically examine the role of rituximab in the treatment of acute graft versus host disease (aGVHD) in critically ill patients and the potential associations with infectious complications in transplant recipients.